Table 2.

Characteristics of transplanted patients (n = 23)

	2000-2007 (n = 14)	2008-2014 (n = 9)
Frequency (%)	61	39
Years at HSCT (median ± SD)	4.4 ± 1.9	10.6 ± 2.6
Indications for high-dose chemotherapy (n (%))
Poor response to chemotherapy in primary local disease	5 (35.7)	5 (55.6)
Primary metastatic disease	6 (42.9)	3 (33.3)
Relapse	3 (21.4)	1 (11.1)
Remission before HSCT (n (%))
Complete remission	4 (28.6)	5 (55.5)
Stable disease/partial remission	10 (77.4)	4 (44.5)
Preparative regimen (n (%))
Busulfan/Melphalan	14 (100)	5 (55)
Treosulfan/Melphalan	0 (0)	4 (45)
Outcome after HSCT (n (%))
Remission	3 (21.4)	4 (44.5)
Progression	5 (35.7)	3 (33.3)
Relapse	6 (42.9)	2 (22.2)
Continuous complete remission (n (%))
Alive in remission	7 (50)	7 (77.8)
Dead	7 (50)	2 (22.2)